Maco Vicente, Marcos Luis, Delgado Jaime, Herrera Julio, Nestares José, Terashima Angelica, Samalvides Frine, Gotuzzo Eduardo
Institute of Tropical Medicine Alexander von Humboldt, Cayetano Heredia University, Lima, PE.
Health Care Center of Progreso, Asillo Azángaro, Puno, PE.
Rev Soc Bras Med Trop. 2015 Jul-Aug;48(4):445-53. doi: 10.1590/0037-8682-0148-2015.
The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica , involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the efficacy and tolerability of 2 schemes of TCBZ.
Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of efficacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment.
A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic.
The tested scheme was efficacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting.
三氯苯达唑（TCBZ）是治疗肝片吸虫的推荐驱虫药，其治疗方案为按10mg/kg体重单次给药；然而，针对儿童的临床试验较少。我们评估了两种TCBZ方案的疗效和耐受性。
84名粪便中检出肝片吸虫卵的秘鲁儿童被分为两组：44名儿童接受两次剂量各为7.5mg/kg的给药，间隔12小时（第一组），40名儿童接受单次10mg/kg剂量给药（第二组）。疗效评估基于粪便中虫卵的存在情况，耐受性评估基于治疗后症状和体征的出现情况。
第一组100%的个体和第二组95%的个体实现了寄生虫学治愈。最常见的不良事件是胆绞痛。
所测试的方案有效且耐受性良好，可能是该地区的最佳方案。据我们所知，这是在非医院环境中接受TCBZ治疗的最大规模儿童系列研究。
